---
layout: post
title: "Issuance of Priority Review Voucher; Rare Pediatric Disease Product; KYGEVVI (Doxecitine and Doxribtimine)"
date: 2026-02-04 21:14:51 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2026-01065
original_published: 2026-01-21 00:00:00 +0000
significance: 8.00
---

# Issuance of Priority Review Voucher; Rare Pediatric Disease Product; KYGEVVI (Doxecitine and Doxribtimine)

**Published:** February 04, 2026 21:14 UTC
**Source:** Federal Register
**Original Published:** January 21, 2026 00:00 UTC
**Document Number:** 2026-01065

## Summary

The Food and Drug Administration (FDA) is announcing the issuance of a priority review voucher to the sponsor of a rare pediatric disease product application. The Federal Food, Drug, and Cosmetic Act (FD&C Act) authorizes FDA to award priority review vouchers to sponsors of approved rare pediatric disease product applications that meet certain criteria. FDA is required to publish notice of the award of the priority review voucher. FDA has determined that KYGEVVI (doxecitine and doxribtimine), approved November 3, 2025, manufactured by UCB, Inc., meets the criteria for a priority review voucher.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2026/01/21/2026-01065/issuance-of-priority-review-voucher-rare-pediatric-disease-product-kygevvi-doxecitine-and)
- API: https://www.federalregister.gov/api/v1/documents/2026-01065

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
